You are here

Article info

Article menu
Review
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis

Authors

  1. Correspondence to Professor Paul Emery, Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds LS7 4SA, UK; p.emery{at}leeds.ac.uk
View Full Text

Citation

Emery P, Sebba A, Huizinga TWJ
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
Annals of the Rheumatic Diseases 2013;72:1897-1904.

Publication history

  • Received February 18, 2013
  • Revised June 20, 2013
  • Accepted July 9, 2013
  • First published August 5, 2013.
Online issue publication 
November 01, 2019

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/